The postoperative course of choroidal- and central retinal thickness in epiretinal membranes with respect to membrane severity

Background: Epiretinal membranes are avascular, fibrocellular membranes which develop on the inner most layer of the retina. These membranes can be idiopathic or secondary to the silicone oil injection after pars plana vitrectomy in patients with rhegmatogenous retinal detachment. When symptomatic, such membranes can cause decreased vision, visual distortion and sometimes diplopia. The purpose of this study was to compare the idiopathic epiretinal membranes versus silicone oil filled eyes epiretinal membranes in terms of their diagnostic and surgical features. Material and methods: The study was conducted at the Department of Ophthalmology, Services Hospital Lahore where 13 eyes with idiopathic epiretinal membranes (ERMs) and 13 eyes with silicone oil filled eyes epiretinal membranes (SOERMs) were evaluated from August 2017 to April 2019. The main diagnostic outcome was the preoperative Optical Coherence Tomographic (OCT) findings and main surgical outcome was peroperative time required for removal of epiretinal membranes. Results: Mean central retinal thickness of patients with SOERMs on OCT was 530.30µm, which was recorded one day before surgery. It was greater as compared to the central retinal thickness in patients with idiopathic ERMs which was 391.92 µm. The mean time required for the removal of SOERMs was 466.38 seconds. It was longer as compared to the time required to remove idiopathic ERMs which was 385.69 seconds. Conclusion: The SOERMs are relatively difficult to remove due to increased thickness and more adherent nature as compared to idiopathic ERMs which were single layer and relatively easy to remove.

Download Full-text

Macular pigment optical density in central serous chorioretinopathy

Therapeutic Advances in Ophthalmology ◽

10.1177/2515841421997195 ◽

2021 ◽

Vol 13 ◽

pp. 251584142199719

Author(s):

Burcu Polat Gultekin ◽

Esra Sahli

Keyword(s):

Confidence Interval ◽

Optical Density ◽

Central Serous Chorioretinopathy ◽

Choroidal Thickness ◽

Retinal Thickness ◽

Macular Pigment ◽

Central Retinal Thickness ◽

Macular Pigment Optical Density ◽

Chronic Central Serous Chorioretinopathy ◽

Acute Central Serous Chorioretinopathy

Purpose: The aim of our study was to evaluate the macular pigment optical density in patients with acute and chronic central serous chorioretinopathy and to describe the association between central retinal thickness and choroidal thickness with the macular pigment optical density. Materials and Methods: Eyes with acute central serous chorioretinopathy and chronic central serous chorioretinopathy (patients, who were diagnosed as having disease activity for 6 months) were included in this study. Macular pigment was measured using the heterochromatic flicker technique of the MPS II device for both eyes in patients with acute and chronic central serous chorioretinopathy and in control subjects. Results: Twenty-seven eyes with acute central serous chorioretinopathy, 23 eyes with chronic central serous chorioretinopathy, and 25 control eyes were enrolled. The mean macular pigment optical density in chronic central serous chorioretinopathy (0.480 ± 0.16 density unit (95% confidence interval: 0.390–0.570) was found to be significantly lower than in the control eyes (0.571 ± 0.128 density unit) (95% confidence interval: 0.480–0.670) ( p = 0.007). In correlation analysis, no significant association was detected between the central retinal thickness, choroidal thickness, and macular pigment optical density values in central serous chorioretinopathy group ( p = 0.31, p = 0.71). Conclusion: Macular pigment optical density levels were significantly lower in chronic central serous chorioretinopathy patients than in controls, possibly due to degeneration of the neurosensorial retina, as a result of the long-term persistence of subretinal fluid. There was not a significant correlation between choroidal thickness and macular pigment optical density levels in central serous chorioretinopathy group.

Download Full-text

Sub-Threshold Micro Pulse Laser (810NM): Treatment for Chronic Central Serous Retinopathy

Pakistan Journal of Ophthalmology ◽

10.36351/pjo.v37i2.1152 ◽

2021 ◽

Vol 37 (2) ◽

Author(s):

Mariam Shamim Kashif ◽

Najia Uzair ◽

Lubna Feroz ◽

Asaad Mehmood

Keyword(s):

Retinal Thickness ◽

Case Series ◽

Central Retinal Thickness ◽

Central Serous Retinopathy ◽

Invasive Treatment ◽

Micropulse Laser ◽

Corrected Visual Acuity ◽

Best Corrected Visual Acuity ◽

Sd Oct

Purpose: To find the effectiveness of sub-threshold (810nm) micropulse diode laser treatment (SMT) in chronic central serous retinopathy (CSR). Study Design: Interventional case series. Place and Duration of Study: Layton Rahmatulla benevolent trust eye hospital, from April 2019 to July 2020. Methods: The patients of chronic CSR (≥ 6 months) participated in the study. We used Spectral Domain Optical coherence tomography (SD-OCT) to record baseline central retinal thickness (CT). Best corrected visual acuity (BCVA) was recorded with Snellen’s chart and converted to Log MAR for statistical analysis. All patients underwent treatment with sub-threshold laser (810nm) in micropulse mode with 5% duty cycle (DC). Results: Twenty five eyes with chronic CSR were enrolled in the study. The patients were treated with laser and final assessment was made at 6 months. Mean BCVA at presentation was 0.46 Log MAR ± 0.12 and a mean baseline CT of 362.2 μm ± 32.6µm. At final follow-up there was a mean decrease in CT of 97.2 μm ± 21.8 from the baseline. After treatment mean BCVA was 0.33 Log MAR ± 0.12 and mean CT was 266 μm ± 20.9. Nineteen out of twenty-five eyes (76%) achieved a gain of vision between 1 to 3 lines and gain of 3 lines was achieved in 8% of cases. At the final follow-up there was incomplete resolution of sub retinal fluid in 4 eyes (16%) with no improvement in BCVA. Conclusion: SMT (810 nm) is an effective and minimally invasive treatment modality for chronic CSR. Key Words: Sub-Threshold micropulse laser, Central serous retinopathy, Central retinal thickness, sub retinal fluid.

Download Full-text

Central retinal thickness fluctuations in patients treated with anti-VEGF for neovascular age related macular degeneration

European Journal of Ophthalmology ◽

10.1177/11206721211037820 ◽

2021 ◽

pp. 112067212110378

Author(s):

Francesco Ciucci ◽

Giuseppina Ioele ◽

Antonio Bardocci ◽

Giorgio Lofoco ◽

Barbara Antonelli ◽

...

Keyword(s):

Macular Degeneration ◽

Retinal Thickness ◽

Treatment Algorithm ◽

Real Life ◽

Principal Component ◽

Age Related Macular Degeneration ◽

Central Retinal Thickness ◽

First Year ◽

Anti Vegf ◽

Age Related

Purpose: This is a retrospective, single-center, non randomized interventional real life study, investigating the correlation between variability of central retinal thickness (CRT) and functional outcomes during 2 years of anti-VEGF therapy in patients treated for neovascular age related macular degeneration (nAMD). Background: CRT fluctuations can depend on various factors such as the correct timing of injections, the therapeutic algorithm, and the number of injections (NI) performed; it is important to understand if CRT fluctuations are responsible for worse visual outcomes and consequently to identify the correct ways to avoid or reduce them. Methods: Forty-one patients were treated for nAMD with aflibercept: 0.5 mg intravitreal aflibercept was administered every 4 weeks during the first 3 months, then bimonthly over the first year, and after the first year adopting a PRN regimen. Standard deviation of CRT (CRT/SD), BCVA, and NI were recorded. Correlation studies were performed by Pearson’s test, Ancova, and Principal Component Analysis. Results: A negative correlation was found between CRT/SD and final BCVA. In patients who lost more than 15 letters, CRT/SD mean was significantly higher in comparison with patients who lost less than 15 letters. Patients with final BCVA >65 letters showed lower CRT/SD values compared to patients with final BCVA ⩽65 letters. Multivariate analysis confirmed that in patients with higher baseline BCVA, improvement of BCVA was correlated to NI, and lower values of CRT fluctuations were observed. Conclusions: CRT fluctuations, even after an appropriate NI given per year, significantly influence BCVA; a proactive treatment algorithm appears crucial when treating patients with nAMD.

Download Full-text

Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies

Journal of Ophthalmology ◽

10.1155/2018/3640135 ◽

2018 ◽

Vol 2018 ◽

pp. 1-9 ◽

Cited By ~ 1

Author(s):

Edoardo Midena ◽

Mark Gillies ◽

Todd A. Katz ◽

Carola Metzig ◽

Chengxing Lu ◽

...

Keyword(s):

Treatment Effect ◽

Retinal Thickness ◽

Continuous Variable ◽

Central Retinal Thickness ◽

Link Type ◽

Intravitreal Aflibercept ◽

Laser Control ◽

Post Hoc ◽

The Impact ◽

Anatomical Outcomes

Purpose. To report the impact of baseline central retinal thickness (CRT) on outcomes in patients with diabetic macular edema (DME) in VIVID-DME and VISTA-DME. Methods. Post hoc analyses of two randomized controlled trials in which 862 DME patients were randomized 1 : 1 : 1 to treatment with intravitreal aflibercept 2.0 mg every 4 weeks (2q4), intravitreal aflibercept 2.0 mg every 8 weeks after five initial monthly doses (2q8), or macular laser photocoagulation at baseline and as needed. We compared visual and anatomical outcomes in subgroups of patients with baseline CRT < 400 μm and ≥400 μm. Results. At weeks 52 and 100, outcomes with intravitreal aflibercept 2q4 and 2q8 were superior to those in laser control-treated patients regardless of baseline CRT. When looked at in a binary fashion, the treatment effect of intravitreal aflibercept versus laser was not significantly better in the ≥400 μm than the <400 μm group; when looked at as a continuous variable, baseline CRT seemed to have an impact on the treatment effect of intravitreal aflibercept versus laser. Conclusions. Post hoc analyses of VIVID-DME and VISTA-DME demonstrated the benefits of intravitreal aflibercept treatment in DME patients with baseline CRT < 400 μm and ≥400 μm. This trial is registered with NCT01331681 and NCT01363440.

Download Full-text

Central retinal thickness assessment in a real life setting after cataract surgery in diabetic patients

Journal Français d Ophtalmologie ◽

10.1016/j.jfo.2018.03.025 ◽

2018 ◽

Vol 41 (10) ◽

pp. 904-909

Author(s):

C. Denier ◽

F. Fajnkuchen ◽

A. Giocanti-Aurégan

Keyword(s):

Cataract Surgery ◽

Retinal Thickness ◽

Real Life ◽

Central Retinal Thickness ◽

Diabetic Patients ◽

Real Life Setting

Download Full-text

Predicting visual outcomes in patients treated with aflibercept for neovascular age-related macular degeneration: Data from a real-world clinical setting

European Journal of Ophthalmology ◽

10.1177/1120672119839299 ◽

2019 ◽

Vol 30 (3) ◽

pp. 543-549 ◽

Cited By ~ 2

Author(s):

Corinne Fulcher ◽

Charlotte A Hazel ◽

Ian Pacey ◽

Hasan Ali ◽

Faruque D Ghanchi

Keyword(s):

Visual Acuity ◽

Macular Degeneration ◽

Predictive Factor ◽

Retinal Thickness ◽

Age Related Macular Degeneration ◽

Central Retinal Thickness ◽

Response To Treatment ◽

Long Term Outcome ◽

Age Related

Background/objectives: There is a significant variation in the way neovascular age-related macular degeneration patients respond to anti–vascular endothelial growth factor treatment. Both the financial and time cost of treatment are significant. As such, being able to predict patient response to treatment is valuable. Subjects/methods: 72 eyes treated with intravitreal aflibercept were retrospectively included in analysis. For each subject, visual acuity (letters) and central retinal thickness (µm) at baseline, second, third and fourth visits, as well as 12-month visits, were collated; a plot of visual acuity versus time was generated and a slope of the first three (slope3) and first four (slope4) visits was calculated. Differences in visual acuity at each visit compared to baseline were determined, as well as percentage differences in central retinal thickness at each visit compared to baseline. Lesion sub-type and the presence of fluid and haemorrhage were also recorded. Results: The average change in visual acuity over 12 months was +3.2 ± 13.4 letters with 91.2% of patients losing <15 letters. Slope4 was the only significant predictive factor for ‘visual acuity change over 12 months’ ( p < 0.001). Change in central retinal thickness, lesion sub-type, haemorrhage at baseline and the location of fluid at baseline were not useful predictive factors in long-term outcome. Conclusion: Aflibercept is an effective treatment option for neovascular age-related macular degeneration; however, the long-term response should not be predicted until at least three loading dose injections have been given. Visual acuity measures at each visit should be examined, as it is the trend in visual acuity across the first four visits (slope4) rather than the difference in visual acuity between two visits that is the predictive factor.

Download Full-text